NEW YORK (GenomeWeb) – Cenix BioScience this week announced it has signed an agreement to provide target-validation services to BASF company Metanomics.
NEW YORK (GenomeWeb) – Cenix Biosciences this week announced that it has signed an agreement to provide RNAi-based high-content screening services to Germany's Bayer Pharma.
Cenix BioScience this week announced that it has signed an agreement to provide its research services to Swiss drugmaker Debiopharm.
Cenix BioScience said this week that its roughly one-year old service contract with Ugichem, a developer of novel gene-silencing therapeutics, has been extended.
The company has added respiratory and inflammation to an RNAi screening program that began with oncology.
The company, which until recently has focused almost exclusively "on cell-based work," expects that the delivery technology will facilitate its in vivo work and enable RNAi-based therapeutics.
The company will use RNAi technologies for cell-based screens for cancer drugs.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.